C1 Esterase Inhibitor use while Breastfeeding
Medically reviewed by Drugs.com. Last updated on May 24, 2022.
Drugs containing C1 Esterase Inhibitor: Berinert, Cinryze, Haegarda
C1 Esterase Inhibitor Levels and Effects while Breastfeeding
Summary of Use during Lactation
C1 esterase inhibitor [human] is a serine proteinase inhibitor derived from human plasma that is used in treating hereditary angioedema. Breastmilk levels of C1 esterase inhibitor have not been measured after exogenous administration in humans. Because of its large molecular weight, amounts in milk are expected to be small. Any C1 esterase inhibitor in breastmilk is probably destroyed in the infant's gastrointestinal tract and not absorbed, except perhaps in neonates. Various international consensus panels state that human plasma-derived C1 esterase inhibitor is considered to be the therapy of choice for both treatment and prophylaxis of maternal hereditary angioedema during lactation.[1-3]
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Three patients with hereditary angioedema received C1 esterase inhibitor concentrate on 12 occasions to relieve abdominal edematous episodes during breastfeeding. No adverse reactions were reported.
In a case series spanning 12 years, 21 mothers with hereditary angioedema breastfed their infants for a median duration of 4.8 months (range 1 to 34 months) while receiving C1 esterase inhibitor concentrate as needed. No side effects occurred in the breastfed infants.
A pregnant woman with severe hereditary angioedema required 500 IU of C1 inhibitor concentrate every 2 days to maintain her pregnancy. Postpartum, she received 500 IU on demand while breastfeeding. She used 88 vitals during her 6-month breastfeeding (extent not stated) period. No side effects or viral transmission were reported and or virus anti-C1-INH antibodies were not detected.
A woman with hereditary angioedema received C1 inhibitor concentrate 1000 units every week during pregnancy. Postpartum she used 500 units as needed. She and her breastfed infant were reportedly healthy.
A woman with hereditary angioedema used subcutaneous C1 esterase inhibitor concentrate 1500 units prophylactically twice a week during pregnancy and postpartum. At 7 weeks postpartum she was able to decrease the frequency to once weekly for 7 weeks, but then increased the frequency to twice weekly until almost 10 months postpartum. During this time, she breastfed her infant although the extent and duration were not stated. There was no mention of any adverse effects in her infant.
A 29-year-old woman with a long history of hereditary angioedema received subcutaneous C1-esterase therapy during pregnancy and postpartum in a dose of “2 x 3000 IU/week” (presumably 3000 IU twice weekly). She breastfed her infant, but the extent and duration of breastfeeding was not specified. The authors reported that the infant experienced no adverse reactions.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Caballero T, Farkas H, Bouillet L, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol. 2012;129:308–20. [PubMed: 22197274]
Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update. Allergy. 2022;77:1961–90. [PubMed: 35006617]
Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9:132–150.e3. [PubMed: 32898710]
Czaller I, Visy B, Csuka D, et al. The natural history of hereditary angioedema and the impact of treatment with human C1-inhibitor concentrate during pregnancy: A long-term survey. Eur J Obstet Gynecol Reprod Biol. 2010;152:44–9. [PubMed: 20541309]
Martínez-Saguer I, Rusicke E, Aygoren-Pursun E, et al. Characterization of acute hereditary angioedema attacks during pregnancy and breast-feeding and their treatment with C1 inhibitor concentrate. Am J Obstet Gynecol. 2010;203:131.e1–7. [PubMed: 20471627]
Farkas H, Csuka D, Toth F, et al. Successful pregnancy outcome after treatment with C1-inhibitor concentrate in a patient with hereditary angioedema and a history of four miscarriages. Eur J Obstet Gynecol Reprod Biol. 2012;165:366–7. [PubMed: 22884590]
Baccioglu A, Kalpaklioglu AF. Successful pregnancy outcome after treatment with C1-inhibitor concentrate in a patient with hereditary angioedema. Allergy. 2014;69 Suppl 99:493–4. Abstract.
Andarawewa S, Aygören-Pürsün E. Subcutaneous C1-inhibitor concentrate for prophylaxis during pregnancy and lactation in a patient with C1-INH-HAE. Clin Case Rep. 2021;9:1273–5. [PMC free article: PMC7981658] [PubMed: 33768824]
Staubach-Renz P. Subcutaneous C1-esterase inhibitor therapy throughout pregnancy and breastfeeding in a patient with hereditary angioedema: A case report. Allergy 2021;76:421. Abstract. doi: 10.1111/all.15095. [CrossRef]
C1 Esterase Inhibitor
CAS Registry Number
Complement C1 Inactivator Proteins
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
More about C1 esterase inhibitor (human)
- Check interactions
- Reviews (7)
- Side effects
- Dosage information
- During pregnancy
- Drug class: hereditary angioedema agents
- En español
- Drug Information
- C1 esterase inhibitor recombinant Intravenous (Advanced Reading)
- C1 esterase inhibitor, human Intravenous (Advanced Reading)
- C1 Inhibitor (Human) (Cinryze)
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.